Clinical Audit of Denosumab Biosimilar for Aggressive GCT of Bone: A Tertiary Care Center Retrospective Analysis
Year: 2025
Type: article
Study design: Observational Study
Abstract: Objectives: Giant cell tumor of bone (GCTB) is a locally aggressive tumor with a high recurrence rate. Using denosumab or its biosimilar in a neoadjuvant setting can facilitate limb-preserving surgery and reduce recurrence rates, with minimal side effects. Material and Methods: In this clinical audit, we retrospectively analyzed the impact of denosumab biosimilar (DB) on Campanacci grade 3 GCTB, the most aggressive form of these tumors. Statistical Analysis: Means and standard deviations were used for normally distributed continuous variables, medians and ranges for nonnormal continuous variables, and percentages for categorical variables. Results: All cases received two doses of DB on days 0 and 14, resulting in a mean lesion size reduction of 17.75%. Conclusion: Our findings suggest that this treatment regimen can significantly improve outcomes for patients with aggressive GCTB, aiding orthopaedic oncologists in managing these challenging cases more effectively.
Source: South Asian Journal of Cancer
Authors: Rajesh B. Singh, Saravana K. Jagannathan, Kumar Vineet
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4409717400